The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative -- Academic Track, 2008Characterization and validation of C. elegans LRRK2 model of PD
Objective/Rationale:
Autosomal dominant mutations in LRRK2 have been identified as a common cause for late-onset PD. Two of the most frequent PD-causing mutations, G2019S and R1441C, occur within the... -
Therapeutics Development Initiative -- Academic Track, 2008Effects of KCNQ (Kv7) Channel Openers in Levodopa-induced Dyskinesias
Objective/Rationale:
Retigabine, a novel well-tolerated antiepileptic drug with analgesic and anxiolytic effects, is an opener of neuronal Kv7 potassium channels. These channels (formely known as KCNQ... -
Therapeutics Development Initiative -- Academic Track, 2008Identification of a novel calcium selective antagonist for neuroprotection in PD
Objective/Rationale:
The objective of the project is to identify a selective and potent antagonist for the Cav1.3 L-type calcium channel. These channels are thought to be responsible for the selective... -
Therapeutics Development Initiative -- Academic Track, 2008Structural and Chemical Approaches to Understand and Modulate LRRK2 Kinase Activity in Parkinson's Disease
Objective/Rationale:
Mutations in LRRK2 cause the most common familial forms, and some sporadic forms, of Parkinson’s disease. Considerable evidence indicates that the neurotoxicity of these LRRK2... -
Critical Challenges in PD: Alpha-synuclein Neuroimaging, 2009Development and Screening of Contrast Agents for In Vivo Imaging of PD
Objective/Rationale:
This project aims to develop reagents to image alpha-synuclein pathology in the brains of living patients as a PD specific biomarker.
Project Description:
Using a library of small... -
Critical Challenges in PD: Alpha-synuclein Neuroimaging, 2009Utility of the Amyloid Ligand [18F]FDDNP in Human PET Imaging in Parkinson Disease
Objective/Rationale:
Biomarkers of Parkinson disease are sorely needed for the assessment of disease status so that they may be used to design more efficient and informative clinical trials of disease...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.